An experimental drug from Novartis AG shrank tumors in more than half of patients with a rare form of lung cancer, in an early-stage study that illustrates how genomic data is reshaping pharmaceutical development and cancer care.. The drug, called ceritinib, targets an anomaly in a gene called ALK that plays a crucial role in about 5% of cases of non-small cell lung cancer—or about 10,000 patients annually in the U.S.. Ceritinib...
  